Global Survey on COVID-19 in Children and Adults with Primary Immune Deficiencies

What this Trial Is About

Researchers are investigating the impact of COVID-19 infection on individuals with primary immunodeficiencies PID, a group for which little information currently exists. The study builds on an earlier survey phase and aims to gather detailed data on how COVID-19 affects survival, hospitalizations, and oxygen therapy needs among PID patients. This observational survey is conducted through a secure online platform and involves global participation by healthcare professionals. The study collects retrospective data from health care providers who enter patient information on a GDPR-compliant system. It focuses on patients of all ages diagnosed with PID and affected by COVID-19. The survey gathers extensive clinical details to better understand outcomes such as ICU admissions and post-infection sequelae. Participants are represented by their healthcare providers who document various outcomes including survival, ICU admission rates, and oxygen therapy use at baseline, as well as longer-term effects. The study began in March 2020 and will continue through February 2027. The data collection is designed to adapt as new knowledge of the pandemic emerges, enhancing understanding of COVID-19s effects on this vulnerable population.

COVID-19 in PID Survey